British American Tobacco p.l.c. (BATS) Earnings Call Transcript & Summary

July 30, 2026

London Stock Exchange GB Consumer Staples Tobacco earnings 69 min

Earnings Call Speaker Segments

Tadeu Marroco

executive
#1

Good morning, everyone. It's a pleasure to have you join us for the presentation of our 2026 interim results. Joining me this morning are Javed Iqbal, our Interim CFO, and Victoria Buxton, Group Head of Investor Relations. I'll start off by covering the highlights of our transformation. After that, Javed will walk you through the details of our financial results. Then I'll come back to discuss our performance outlook in greater depth and explain why we feel confident about the path ahead, in light of the clear momentum that is building. Following that, we'll open things up for your questions. On that note, I'd like to point you to the disclaimers on slides 2 and 3. Let's start by examining our transformation momentum, beginning with a few highlights from H1. Smokeless products now account for 19.8% of group revenue, which is up 160 basis points compared with last year. Over the past 12 months, we added 4.1 million smokeless consumers, bringing the total to 35 million. This progress is largely fueled by growth in the modern oral industry, where the Velo brand's strength keeps resonating strongly with consumers. Our first half results came in line with expectations, backed by a strong multi-category delivery in the US, excellent Velo momentum across all three regions, and a resilient combustibles performance in the US and AME.

Tadeu Marroco

executive
#2

Our disciplined emphasis on growth with quality keeps enhancing returns via more focused investments, and new category contribution rose 55% at constant rates. As we guided earlier, adjusted profit from operations should speed up in H2, powered by gains in AME and APMEA. The second-half weighting also stands to gain from how Fit to Win savings are phased. Lastly, we keep producing robust cash returns. By year end, we expect to sit inside our 2 to 2.5 times target leverage corridor, even as we keep rewarding shareholders through our progressive dividend and a £1.3 billion share buyback in 2026. The momentum we are building as we transform BAT encourages me. New categories are turning into a more and more meaningful contributor to group performance, which strengthens our confidence in sustainable delivery going forward. Having been through a period of investment and transition, getting back to our algorithm for the full year marks an important milestone. It mirrors the progress achieved in reshaping the business and gives a stronger foundation for creating long-term value. With that, I will pass things to Javed, who will walk you through our financial performance in greater detail.

Javed Iqbal

executive
#3

Thanks, Tadeu, and good morning, everyone. I'm glad to report that on a constant currency basis, our results came in as expected. The main drivers were robust multi-category delivery in the US along with faster growth in new categories. A number of adjusting items show up in our reported results, most of them non-cash: roughly £800 million mainly tied to annual amortization of our US trademarks, a £370 million one-off adjustment connected with Fit to Win — about £230 million of that non-cash — and a £149 million credit from settling historical litigation. So you get a clear picture of underlying performance, I'll concentrate on constant currency, adjusted, and, where relevant, adjusted for Canada metrics. More detail on adjusting items and share data is in the appendix. Momentum kept building through the first half, which strengthens our confidence in hitting full year guidance. Group revenue was up 2.9%, adjusted gross profit climbed 3.8%, adjusted profit from our operations rose 3.5%, and adjusted diluted EPS increased 7.9%. Turning now to new categories: revenue growth sped up to 18%, powered by yet another excellent showing from modern oral, which gained 66%. Vapour revenue was 5.3% higher, led by the US, where we got back to double-digit volume and revenue growth.

Javed Iqbal

executive
#4

That was partly offset by a drop in heated products, as glo revenue fell almost 12%, hit by inventory movements and competitive intensity in the value segment. We keep delivering quality growth, with gross profit rising by more than £120 million and category contribution climbing 55% to reach £269 million. That reflects our disciplined approach to investment and growing scale benefits. We stay committed to investing behind profitable growth in vapour and heated products, and specifically we are becoming increasingly selective about where we deploy our resources, which Tadeu will discuss further later. Now turning to combustibles. Combustible volumes declined 4.7%, as growth in Pakistan and Turkey was more than offset by continued industry volume decline in other key markets plus the impact of market exits in Cuba and Mozambique. Revenue rose 2.1%, driven by robust price mix of 6.8%. Growth in the US and AME more than offset a slower than expected recovery in APMEA, as fiscal and regulatory pressure persist. Adjusted gross profit and category contribution both grew ahead of revenue, driven by a strong performance in the US, positive price mix, and our continued focus on cost optimization. Combustible remains a powerful value engine for the group, delivering robust returns and continuing to fund our transformation.

Javed Iqbal

executive
#5

Our performance has held up well, and that speaks to how broad our global footprint is, how strong the portfolio is, and how disciplined we've been in execution. Now moving to our regions, and beginning with the US: we posted a strong performance across multiple categories, which pushed total revenue up 8.5% and adjusted operating profit up 10.1%. Revenue from new categories rose by nearly 60%, fueled by the ongoing success of Velo Plus, which climbed more than 200%, along with Vuse, which got back to double-digit growth in both volume and revenue. Within combustibles, revenue was up 5%, helped by robust price mix, including gains from excise duty drawback and favorable trade inventory movements. Value share fell by 40 basis points, while volume share dropped 80 basis points, a reflection of continued industry growth in the deep discount segment and heightened competitive activity since Q4 last year. We've responded actively to that trend, putting investment behind our portfolio and further strengthening how we execute commercially. Because of that, we've held our volume share since January. As we look toward the second half, we anticipate an acceleration of investment to support the launch of Velo Max and Vuse flavour pods, as well as behind our combustible portfolio in a market that is highly dynamic. Tadeu will go into this in more detail later. Beyond that, we expect our strong H1 growth to moderate in H2, since positive inventory movements won't repeat and we lap a stronger comparator.

Javed Iqbal

executive
#6

For AME, total revenue grew 0.9%, with combustible up 2.5% and new category up 1.9%. That was partly offset by lower direct leaf sales, which reflects our ongoing focus on higher-return, more profitable areas. The combustible revenue came from strong delivery in Brazil, Turkey, and Mexico, along with robust price mix. That was partly offset by our exit from Cuba and increased competitive pressures in Germany and Romania, where we've taken targeted actions to strengthen our portfolio. On new categories, modern oral revenue rose 22%, driven by the strength of our portfolio across both established oral markets in Scandinavia and newer growth markets, including the UK and Poland, which now make up around 50% of our modern oral revenue in the region. Heated product revenue fell by nearly 11%. Growth in Romania and Portugal was more than offset by lower revenue in Italy and Poland, due to heightened competitive activity in the value segment. Going forward, we expect to strengthen our value proposition with the next-generation Hyper Pro Plus in the second half of the year. We're also encouraged by the continued momentum of glo Hilo, which is performing well in the premium segment. Vapour revenue declined 14%, mostly impacted by regulatory changes in Poland, as we continue to focus our investment on larger industry value pools.

Javed Iqbal

executive
#7

Adjusted operating profit was up 1.1%, helped by ongoing resilience in combustibles and quality growth in Velo and Vuse. That gain was partly offset by investments in heated product tied to the rollout of our innovations. We expect performance to speed up in H2, driven by our targeted commercial actions and the benefit from rolling out new category innovations. Moving to APMEA, where recovery has come more slowly than we anticipated, revenue fell 6.3%, mainly because of combustibles. We keep driving growth in key markets, Pakistan and Indonesia among them, but that was more than offset by a difficult regulatory environment and the impact of illicit volume in Bangladesh and Australia, together with the timing of inventory movements in Vietnam. Modern oral revenue rose 43%, driven by our first-mover advantage and category leadership across emerging growth markets. Those include Japan, Pakistan, South Africa, and global travel retail, which highlights the growing opportunity for the category and for Velo. Heated product revenue dropped 13%, hit by material inventory movements and heightened competitive intensity in the value segment in Japan. On an encouraging note, glo Hilo keeps building momentum in the premium segment, and with Hyper Pro Plus launching in Japan in Q3, we expect share performance to improve in H2.

Javed Iqbal

executive
#8

Vapour revenue fell 28%, which reflects deliberate exits from certain markets and a more targeted approach to allocating resources. Adjusted profit was down 16.5%, largely because of headwinds in key combustible markets. Going forward, we anticipate additional sequential improvement in performance during H2, backed by our commercial initiatives and investments across both combustibles and new category, along with a softer comparator in Australia. Moving now to our group operating margin, which rose 30 basis points to 43.7%. We managed to offset inflationary pressures through a strong performance, greater profitability in new categories, and ongoing cost savings. At current rates, operating margin grew by 10 basis points. We are making solid progress on Fit to Win, our transformation program aimed at building a leaner, faster, and more data-driven BAT. We have found a further £100 million in optimization savings, which brings an incremental one-off £100 million cash investment to support delivery. Beyond that, to further drive new category growth, we have also finished a comprehensive review of our manufacturing assets and machinery. Through this, we have identified opportunities to upgrade to more efficient, next-generation technologies and state-of-the-art machinery to support future growth and productivity, and to accelerate our transformation. Consequently, we have recognized a non-cash charge of nearly £230 million in the first half.

Javed Iqbal

executive
#9

All told, we now anticipate £700 million in annualized savings by 2028, and £500 million of that should be delivered by 2027. One-off costs total £950 million at this point, with £840 million treated as adjusting. Our expectation remains that most of the cost lands this year, and the balance in 2027. Pulling that together, earnings per share rose 7.9%, as operating profit growth was aided by 4.4% growth from earning kickers. That outperformance came mainly from a lower net finance cost — reflecting debt repayment funded by proceeds of the partial ITC stake disposal in May last year — plus stronger operating cash conversion in H1. Turning to the full year, net finance cost is now expected at roughly £1.65 billion, with an underlying tax rate of between 24% and 25%. Consequently, full year EPS guidance has been upgraded, and earning kickers should be moderate as we annualize the benefit of lower debt levels. Robust cash generation keeps strengthening our financial flexibility and underpins disciplined capital allocation. We stay on track to sit within our 2 to 2.5 times leverage target range by year end, and to generate more than £50 billion of free cash flow by 2030.

Javed Iqbal

executive
#10

Our capital allocation priorities remain unchanged: putting money into transformation, balancing deleveraging against a progressive dividend and sustainable share buybacks, and pursuing selective bolt-on M&A that supports the transformation. In summary, H1 came in as expected, and we remain on track to deliver our mid-term algorithm for the full year, with profit weighted toward the second half. The main drivers for H2 are: mid-teens revenue growth in new categories, led by Velo and Vuse, which will drive a further improvement in new category contribution; an acceleration in performance across AME; additional sequential recovery in APMEA; and strong H1 US growth moderating, reflecting increased investment, lapping a stronger comparator, and the fact that positive inventory movements do not repeat. We expect H2 performance to get further support from the positive phasing of Fit to Win benefits. As we guided previously, revenue and operating profit for the full year should land at the lower end of this range, absorbing roughly a 1% transactional FX headwind and reflecting active investment choices, including the roll out of Velo Max and Vuse flavours in the US, scaling the glo Hilo and Hyper Pro Plus launches, and increased combustible investment in the US and other key markets. Lastly, we now expect full year EPS growth towards the middle of our 5 to 8% range.

Javed Iqbal

executive
#11

Appreciate it — I'll now return the floor to Tadeu.

Tadeu Marroco

executive
#12

Thank you, Javed. As we look forward, the momentum we're building gives me confidence — we're getting back to our algorithm and continuing BAT's transformation. We're moving into the next stage of this journey from a position of strength, with financial delivery speeding up, new category profitability improving, and an obvious route to long-term growth and value creation. Against that backdrop, I'd like to go deeper on our progress, focusing on the subjects you, our investors, ask us about the most. Let's begin with how durable our multi-category delivery is in the US. Consumer behaviour around adult nicotine is shifting meaningfully throughout the market. BAT sits fully in line with the direction these consumers are taking, thanks to our unique multi-category portfolio holding number one or number two share positions in every category. That makes us, as of now, the company growing fastest in total nicotine. Our share of total nicotine volume has risen 110 basis points year to date, powered by new categories, with Velo accounting for roughly 90% of modern oral value growth and Vuse contributing more than 100% of vapour value growth. My point is simple: we think no one is better placed to win in total nicotine and to keep capturing value in the world's largest nicotine value pool.

Tadeu Marroco

executive
#13

Now let me walk you through the US market category by category. To begin with combustibles, where we keep balancing disciplined investment against creating sustainable value. Industry volume kept getting better during the first half, falling 4.9% on a sales-to-retail basis. That improvement was helped by moderating declines in solo's consumption trends, a slowdown in outflow to illicit vapour — aided by regulatory enforcement actions — and deeper discount expanding into tracked channels, which we expect the industry to lap in the second half. Our focus stays on generating value and share from our combustibles business, and as Javed highlighted, we keep delivering strong financial performance in H1. Against that backdrop, we have observed heightened competitive activity since Q4 last year. We have already taken steps to further sharpen how we manage the portfolio, strengthen our route to market, and leverage digital revenue growth management capabilities. Beyond that, we have been actively investing to strengthen the portfolio, and encouraging results are starting to appear. Targeted investments have been supporting Newport in premium, and we have been strengthening Camel as well. Together, Lucky Strike and Pall Mall Select keep driving gains in both volume and value share within branded value, which — combined with taking our Doral brand coverage out to five states — is reinforcing our presence and competitiveness at the low end of the market.

Tadeu Marroco

executive
#14

So because of that, our volume share has stayed where it was since January, and we'll keep investing actively behind our portfolio through the second half. Second, people frequently ask me about how the regulatory and enforcement picture looks in the US. It's encouraging that we're beginning to see recent actions making a difference for irresponsible illicit operators, while at the same time giving responsible legal manufacturers a route to bring scientifically backed products to market. We're now seeing several government measures start to tackle the imbalance that has long existed between the legal market and illicit operators. First, state directory and enforcement frameworks now cover around half of vapour industry volume. Second, federal cross-agency collaboration has led to seizures of more than 18 million unauthorized vapour products. Third, the FDA is acting to strengthen regulatory compliance for foreign manufacturers. Finally, Attorneys General keep ramping up pressure on illicit vapour sales channels and payment providers. Importantly, these actions have helped the legal vapour industry get back to growth in H1. We're also encouraged by the FDA's new prioritization guidance, which backs a pathway for both vapour flavours and modern oral innovation. All together, these developments help create a more level playing field. In US vapour, Vuse keeps reinforcing its leadership position.

Tadeu Marroco

executive
#15

In the first half, we pushed value share up to a record 55.9%, and our share is now more than twice that of the closest competitor. Building on that leadership position, we'll start a phased rollout of new adult-focused Vuse flavours, which widens consumer choice and levels the competitive playing field, beginning in Q3 with distribution to roughly 25,000 outlets. We'll carry out this expansion in a disciplined way, maintaining our high standards for product quality, retailer compliance, and preventing underage access. Distribution will be carefully targeted, as we collaborate with retailers to secure their commitment to adult-only sales, which supports category sustainability. All of this gives us confidence in Vuse's ability to keep growing and to further strengthen its competitive advantage in the world's largest vapour market. Third, I'm often asked about the growth opportunity that lies ahead in modern oral globally. In the US, I'm excited about expanding our Velo portfolio in that rapidly growing market. Velo Plus keeps delivering outstanding performance, with our overall modern oral volume share now at 31% and value share at nearly 26%. Beyond that, we're capturing around 90% of category value growth, which shows both the strength of the product and brand and the effectiveness of our commercial execution.

Tadeu Marroco

executive
#16

Expanding the Velo portfolio further, we're building on that success to reach a wider span of adult consumer preferences, and that includes bringing out limited-edition Velo Plus variants. Velo Max, a product with higher moisture and our newest innovation in the US, arrives starting Q3. With two new strengths and four new flavours, this broadens what we offer, complements the existing portfolio, and gives us an additional growth lever. In modern oral — the category growing fastest and carrying the lowest risk profile — Velo is plainly the global number one brand. As regulatory clarity improves, we keep extending Velo's footprint: 32 markets have adopted category regulation so far, more than double the count versus 2024. Strong growth in all three regions, together with successful execution of our premiumization and innovation strategy, keeps reinforcing our clear leadership position. Our scale advantage keeps widening. BAT shipped 7.9 billion pouches in the first half, and in our top markets our modern oral volume share rose by over 8 percentage points, reaching 39%. With the category growing quickly, we believe a superior portfolio backed by continuous innovation, scale, brand strength, and regulatory capabilities will matter more and more as competitive advantages.

Tadeu Marroco

executive
#17

When it comes to AME, BAT is plainly the category leader, holding a 62% volume share across our top markets, which makes us almost seven times the size of our closest rival. That leading position rests on our superior brand equity scores — 40% higher than our nearest competitor in Europe — which back our premium brand positioning and show up in our 68.5% value share. We keep delivering strong, volume-led revenue growth, and importantly, that growth is increasingly broad-based. Roughly 50% of our revenue originates outside the Nordics, where the category keeps developing through growing incidence and consumption, helped by expanded distribution, rising category adoption, and the strength of the Velo brand. Innovation stays a key differentiator. With Velo SHIFT, we are extending our premium positioning. Progress in Sweden and Switzerland is encouraging, with SHIFT capturing 1% of value share in Sweden and 1.5% in Switzerland within a few months of launch. All in all, our strong momentum gives us confidence in our ability to keep driving sustainable, profitable growth and value creation in modern oral. Fourth, I've been asked about our key drivers of performance improvement in heated products. We are resetting glo's performance with a sharper, more disciplined approach. Industry volume growth moderated further in the first half, reflecting excise-driven disruption in Japan and continued consumer poly-usage across vapour and, increasingly, modern oral globally.

Tadeu Marroco

executive
#18

Meanwhile, rivalry in the market has become more intense. With that in mind, our investments are being directed toward areas offering the greatest consumer opportunity and the highest potential returns, within a value pool that is still substantial at £9 billion. We're expanding glo Hilo to drive premium growth, while reinforcing our value offering through Hyper Pro Plus. Beyond that, we're directing resources toward priority markets in a more selective manner. The result is a clear focus: reset performance and rebuild share momentum in H2, achieved via innovation-led growth and disciplined execution. glo Hilo is starting to show the advantages of our premiumization strategy. Rolled out in nine target markets that represent roughly 70% of industry volume, it gives us a solid foundation for scaling in the future, with approximately half of consumers being new to the glo platform. We're also reinforcing glo's brand equity as we build our position in the premium segment. This is turning into concrete commercial gains, with volume share rising across key markets and especially strong momentum in Poland. We remain focused on scaling glo Hilo by driving trial, targeting buyers of premium combustibles and heated products, while raising awareness to unlock additional growth. And finally, bringing everything together.

Tadeu Marroco

executive
#19

As we carry that momentum forward, we can see an obvious route to better growth in 2027. Four main drivers will underpin what we deliver. First, new category revenue should keep growing strongly, powered by ongoing momentum in modern oral, vapour led by the US, and a sharper, more focused approach in heated products. Second, we expect steady combustibles performance, helped by additional recovery in APMEA and by focused investment aimed at driving combustibles value and share sustainably around the world. Third, profit conversion should remain strong, reflecting better returns in new categories and continuing cost savings. Fourth, EPS will benefit from share buybacks, reduced finance costs, and continued robust cash generation. In closing, by directing investment toward the opportunities with the highest returns, we are producing quality growth across our multi-category portfolio, backed by tighter execution, stronger capabilities, and disciplined allocation of resources. Through all of this, we are generating better returns and making the business more resilient. Simultaneously, we are strengthening financial flexibility, which allows us to keep investing in our transformation while also delivering attractive cash returns. I have confidence in our strategy and in how we execute, and I believe BAT is well placed to create long-term value for shareholders. Ahead of the Q&A, let me highlight several key themes that will shape BAT's coming phase of growth and value creation.

Tadeu Marroco

executive
#20

We’re eager to share additional details during our Capital Markets Day in September. Thanks for listening. At this point, I’ll turn things over to Victoria, who will introduce the question-and-answer session.

Victoria Buxton

executive
#21

Thanks, Tadeu and Javed, and good morning, everyone. Should you be with us on the webcast, you're able to type your questions straight into the online question box. Alternatively, if you're on the call, just press star one on your telephone keypad. Tadeu and Javed will be very happy to take your questions, and at this point I'll hand things over to the conference call operator.

Operator

operator
#22

Thanks. Our opening question comes from Andrei Andon-Ionita at Jefferies. You have the floor.

Andrei Andon-Ionita

analyst
#23

Good morning, Tadeu, Javed, and Victoria — thanks so much for taking my questions. I have two, please. First, regarding US e-vapour, do you expect those illicit enforcement tailwinds to carry on into early H2? And for the Vuse Ultra launch in H2, could you give us a little more colour on what we should expect when it comes to the number of outlets targeted and the types of flavours we should see on the market? Then on US combustibles, you posted plus 5% top-line growth in H1, well ahead of the US combustibles framework of value flat to plus 1% growth. How should we think about the US combustibles algo for the full year 2026, given this H1 performance? Thank you very much.

Tadeu Marroco

executive
#24

Thanks, Andrei, for that question. I'll begin with the combustible figures. You're right to note that the 5% performance in H1 runs well ahead of what the algorithm would imply. We've been flagging that certain trade movements helped us in H1 and will reverse in H2. That accounts for roughly 2% of the 5. So underlying performance is really closer to 3%. There's clearly momentum in H1. Duty clawback forms part of that 3%, though it isn't a big piece of it. Most of the performance is organic, to put it that way. As we noted in the presentation, we plan to keep investing behind our portfolio as we move through the second half. We're plainly seeing the low discount segment in the US keep growing, and we're working to be more competitive there too. I'd expect a more moderate performance in the second half, especially in combustible in the US, which should show up in a number much nearer the algorithm — perhaps still somewhat above the 0 to 1 we have, but not as high as in the first half.

Tadeu Marroco

executive
#25

That's the combustible side. On the vapour side, what we're seeing from state enforcement is very encouraging. 50% — that's the first time we've witnessed the legal vapour market recovering, on a very modest base, but even so, for the last few years we've watched the legal market decline year after year. It's difficult to say precisely what will happen next. Given all the initiatives I highlighted during the presentation, I'd suggest we could expect at least a similar kind of environment. I wouldn't call that significant, I would say. What encourages me more is the prioritization guidance coming from the FDA, since it lets legal American manufacturers provide substantiated high-quality products to adult nicotine smokers in the US. That translates into our ability to restore flavours in the market and to have a more level playing field, because you can't forget that on one hand enforcement is an important element, and there is clearly an uptick in enforcement levels, mainly at the state level, but the root cause of illegality comes down to an absence of a level playing field. Achieving a higher level playing field will also be very important.

Tadeu Marroco

executive
#26

I'd anticipate that we keep gaining a bit more ground in the legal vapour market. As for what you asked about

Javed Iqbal

executive
#27

Turning to flavors and the way we roll them out.

Tadeu Marroco

executive
#28

As for how we roll this out, we said it would essentially happen in 2 phases. During Q3, we'll reach 25,000 outlets. Why take that approach? Because we've been quite deliberate about how we bring flavours back into the market. We want to ensure retailers perform the ID scan before selling these products, so that there's no youth access to them. There's a commitment and a compliance methodology we're putting in place, and that's why we're being so deliberate about how we roll this out. The plan is to go in Q3 with 25,000, then in Q4 there's another round of 25,000, but we'll build from there, okay?

Operator

operator
#29

Thanks. We'll take the next question from Faham Baig at UBS. Go ahead, please.

Faham Baig

analyst
#30

Morning, everyone. Thanks for taking my questions too. I have a couple as well. First, on nicotine pouches in the US, could you help us understand how quickly Velo Max is being rolled out in terms of distribution stores, and what the likely economics look like versus Velo Plus? Of course, you've now seen competitors launching their own improved versions of nicotine pouch products. How have you seen that affecting competitive and category dynamics so far? My second question is on full year 2026 guidance. Maybe you could elaborate on some of the moving parts you expect in the second half regarding how the 2.9% organic sales growth develops, what might see it do better, what might see it do worse, and what are the three key items you'll be monitoring? Okay. Faham. Look,

Tadeu Marroco

executive
#31

Regarding nicotine pouches, we already have a highly established network thanks to Velo Plus in the US. It simply comes down to the usual amount of time required to distribute across a continental country such as the US. This will likely be quicker than what it took us with Velo Plus, since we now have a well-established network, which wasn't necessarily the situation when we first launched Velo Plus. It takes some time to reach where we are with Velo Plus, but the plan is to use Velo Max as a complement to Velo Plus. From a commercial standpoint, we'll obviously be taking our competitors' position into account, and we want to make the product as competitive as possible, giving consumers a chance to try it. We believe it's an even enhanced product, because as I said, it has higher moisture and different strengths, and I think that will address some consumer needs that Velo Plus isn't necessarily currently positioned for, when we consider, for instance, higher levels of strengths, and obviously also different flavours. That's why we say that distinct flavours will complement their portfolio. We feel very, very — I would say we obviously are very, very supportive of Velo, very good about the products we have on the market.

Tadeu Marroco

executive
#32

It's clearly a competitive market, and there's no question it will get more competitive. We're seeing how strong Velo Plus is in supporting all these new launches from the competition, and I really do think I will remain a very strong brand. Right now we lead in 11 states across the US, and our retention rates sit at 70%, which hasn't changed. Essentially all of the category's growth in the first half comes from Velo Plus, regardless of the launches we've seen so far. I truly believe we have everything needed — with the capabilities we've built and the product we have, now complemented by Velo Max — all the conditions to back the position we hold in the market. As for the building blocks for the second half of the year, and obviously APMEA, we expect performance in the second half to be better than in the first half. It's clearly a recovery story. H1 2026 for APMEA was already better than the H2 2025. H2 2026 will be better than H1 2026, because we'll be lapping softer comparators, if you will, in places like Australia, for example.

Tadeu Marroco

executive
#33

As you may recall, they brought in a very harsh regulation that caused illicit trade in Australia to speed up dramatically during the latter half of last year, and we'll be lapping that. That will be more positive. Clearly that's going to be the driver for the second half, and that's why we're saying the year is weighted mainly toward the second half, largely due to how APMEA is performing. In AME, we've been putting substantial investment behind mainly combustible and HP, and we expect some improvement there in the second half as well. On the US, we just talked about the US, I don't expect that 5% to continue in combustible for the remainder of the year, and that's because of the investments we need to make in the combustible portfolio. Overall, that's why I expect a more positive second half for the group as a whole, and that leads to a full year in terms of top line at the low end of our range. Do you want to add something? I think and

Javed Iqbal

executive
#34

In the same way, that also applies to the components driving the top line. As we guided, we expect very strong performance in the US, but AME and APMEA will deliver an even stronger performance compared with H1, while the US will be slightly less strong. Putting all of that together, we land once again at the lower end of our algorithm for the full year. That marks the first time we are entering the algorithm. Second, as I mentioned earlier, on EPS guidance, the overall impacts will slow down across the full year, but we will see a strong kicker. That is the reason we have guided an upgrade to our EPS guidance, taking it to the mid of the range.

Tadeu Marroco

executive
#35

I just want to add something on that point, because I got a few questions about the low end of the range. What we're thinking about here is the long-term sustainability of the algorithm. We're making the right investments for the business, for sustainable growth of the business. We need to invest in combustible in the US, and in some other key markets as well. We need to invest in that excellent performance we have in modern oral across the world. We're resetting our HP business, which also calls for investments with the launch of glo Hilo. And in vapour in the US, we obviously always have an opportunity that we haven't seen in many years. We're doing the right things for the business for the long run. As we've always said, this is a year to go back to the algorithm. We're positioning at the low end to create the possibility for us to make the right investments to make this a sustainable story moving forward, and I'm very confident that will be the case.

Faham Baig

analyst
#36

Thanks, Javed and Tadeu.

Operator

operator
#37

The following question comes from David Roux with Morgan Stanley. You have the floor.

David Roux

analyst
#38

Much appreciated, and good morning to you both, Tadeu and Javed. I'll start with a question about combustibles. Back at the June trading updates, as I recall, the business cut its forecast for global cigarette industry volumes from -2% down to -2.5%. You mentioned at that point, I believe, that Bangladesh was mainly responsible. Now it looks like the assumption has been reduced once more, this time to -3%. So what's behind this newest downward revision to the industry cigarette volume outlook? Has the situation in Bangladesh gotten worse, or are you seeing broader softness in other markets as well? My second question concerns Velo in the US, and it has two parts. Taking a broader view, after Velo Max rolls out over the remainder of this year, how many SKUs spanning strengths and flavours do you anticipate having across the entire Velo platform at the close of this year compared with, let's say, today's position? The second part is this: your main US competitor in nicotine pouches recently got a modified grant order allowing it to market with a reduced-harm claim. In your view, does that modified grant order genuinely make a difference on the marketing side, and will you be seeking the same thing for Velo?

David Roux

analyst
#39

Thanks.

Tadeu Marroco

executive
#40

All right. Let's take on the combustible question. The 2.5 to 3 figure is essentially driven by Brazil. We experienced a huge excise shock there, with prices taking effect on August 1st. That's genuinely a significant excise-driven price hike. Clearly, it will affect how big the market is, and that market is large — Bangladesh is a large market too — but the driver is essentially Brazil. On Velo, we already offer three strengths of Velo Plus. We now have two additional strengths, so in total Velo will carry five strengths. Obviously, that's where we stand today. What gives us encouragement regarding this prioritization guidance from the FDA is that we will be able, with greater certainty, to deliver more innovative products to market in due course, which really hasn't been the situation for many, many years. We have been submitting PMTAs and have been at it for a long, long time. That is about to change under the new guidance. For the time being, we will proceed with the launch of Velo Max in five different strengths, with the Velo family shifting from where it stands today. As for your comments on the questions about

Javed Iqbal

executive
#41

MRTP?

Tadeu Marroco

executive
#42

I'd say having MRTP status for modern oral is a welcome development for the category as a whole. In my view, there aren't any significant commercial advantages tied to a specific SKU or product on the market. We do have Velo MRTP applications in the pipeline as well, and we could potentially receive one of those before too long. The point isn't so much the commercial opportunity in the market — it's more about what it signifies for advocacy of the category, particularly when it comes from a market like the US with the FDA. That, as you know, matters a great deal. We've been extremely far ahead when it comes to discussions with a range of stakeholders aimed at properly regulating this category, since we regard it as the lowest-risk one among the new categories, if you will, given that there's no inhalation and no tobacco — it's the closest thing you can get to NRT-type products. As I mentioned in my presentation, we now have 32 markets where modern oral is regulated. Several of those markets are in Europe, which is also very important. Developments like this one, with MRTP being delivered by the FDA, are very positive overall. The commercial impact in the local market matters less; what counts more is advocacy for the category, even beyond the US.

David Roux

analyst
#43

That's very clear. Thank you.

Operator

operator
#44

Thanks. We’ll take the next question from Gerry Gallagher at Deutsche Bank. Go right ahead.

Damian McNeela

analyst
#45

Good morning, and thanks for taking the questions. A few from me. First, on the new categories portfolio, I believe you've decided to exit some vapour markets and reprioritized in heated. Could you indicate whether that work is now complete, or whether there are still markets where you're examining the viability of those categories? That's the first question. Second, can you give a bit more detail on what specifically is happening in the German combustibles market regarding increased competition, and whether there is anything you can do, or what you are doing, to combat that increased competition? Then the last one follows up on Faham's question earlier. Are you able to give any indication of relative pricing for Velo Max in the US when it launches, please?

Tadeu Marroco

executive
#46

Alright, beginning with the last one: no, we aren't providing any indication of what Velo Max will cost. Regarding Germany, what we've observed across the past 2 years is mainly trade labels brands growing within that market. Lately, that growth has steadied somewhat. This has produced some downtrading pressures in the market, which clearly we need to respond to. We aren't seeing growth at the pace witnessed previously in trade labels. It appears we're moving toward a more stable situation, but that's the dynamic across the past 2 years, to put it that way, and more recently 18 months, I'd say. When it comes to

Javed Iqbal

executive
#47

We're going to exit Vapour and put our focus back on HP.

Tadeu Marroco

executive
#48

When it comes to HP, in vapour markets, our main decision is to exit Asian markets where we see neither an appropriate regulatory framework nor enforcement. Consequently, a legal company such as BAT gets no financial return, since we must compete against illegal products and, if you like, there is no level playing field. We chose to pull out of a number of markets we had originally entered once they became regulated, expecting that regulation would be made compliant. That did not happen, we have to accept it, and since we are constantly seeking the best return on our investments in terms of resource allocation, we make the call to exit. That is why you see vapour numbers in APMEA in particular turning negative as a result of these exits. In AME, it is more a result of a legislative change in Poland that essentially makes it completely unviable to remain in the vapour market anymore. Also in the UK, with the policy changes, again, another market where assessing compliance is very difficult. The latest figures I have seen there show a very, very strong presence of illegal products in the UK market.

Tadeu Marroco

executive
#49

This is something we’ll keep reassessing, I have to say. I’ll tell you that we have already acted on most of it. There will probably still be some impact coming across the H2 of this year, and as we lap this for next year onwards, it becomes less evident about these market exit decisions, okay?

Damian McNeela

analyst
#50

Thanks. That’s very clear.

Operator

operator
#51

Thanks. We’ll take our next question from Pallav Mittal at Barclays. Go right ahead.

Pallav Mittal

analyst
#52

Morning, everyone. Thanks for taking my questions. I had some technical trouble earlier, so apologies if I missed anything. First, on the US combustibles business: volumes look better while price mix is slightly lower than our expectations, and I believe your comment noted that duty drawback isn't a big contributor on the mix side. Could you size the volumes benefiting from duty drawback, and is that growing sequentially or has it leveled off now? That's my first one. Second, on your vapour business in Europe: it's faced pressure for the past couple of years, and you've recently flagged issues in Poland and elsewhere, but how should we view that European vape business over the medium term?

Tadeu Marroco

executive
#53

Alright. Regarding vapour in Europe — yes, the main factor weighing on those figures ties back to Poland. We've held strong positions in markets such as Germany, which is a really, really significant vapour pool. The Vuse Ultra, for instance, is gaining substantial ground there. In other markets such as France and Spain, plenty of competitors are entering, yet we also have a very robust pipeline arriving in H2. We're confident in our capacity to maintain our leadership position in vapour across Europe in the markets we've chosen to compete in. That's the first point. On combustible, as I said, the industry — I'll address the industry first — we've observed a slowing in the rate of decline. As I highlight in my presentation, much of that stems from growth at the low end of the category, which, if anything, is expanding rather than shrinking — it keeps growing. We're seeing less migration away from cigarettes toward illegal vapours, and essentially for two reasons. First, availability of these products becomes more constrained as more states pass legislation, which is happening now — 50% of where the volume is sold.

Tadeu Marroco

executive
#54

There's also the reality that we have a larger number of solo users of combustibles who simply don't wish to switch over to the vapour side. Taken together, this is producing a dynamic that's more favourable than what we saw previously. It's difficult to forecast how things develop going forward, because if anything, we still need to observe the correlation with oil price and the conflicts taking place in the Middle East, and how that might affect oil price, since we know a correlation exists between oil price and cigarette consumption in the US. We haven't observed this yet in the H1, but it's hard to predict for the second half of the year. Obviously, what we'll be doing, and will be reflecting in our top-line numbers, is we will be stepping up our competitiveness so we can respond to the fact that the lower end of the market is growing. That's one element that will have an implication in the second half of the year. The other element, as I mentioned earlier, is the inventory movements that have an impact of around 2% of revenue that will be lapping in the second half of the year. It's not a reflection of the underlying performance, if you like, of the first half of the year.

Tadeu Marroco

executive
#55

That's the primary factor behind our expectation that, for the US, performance will lean toward H1, whereas the rest of the group will lean toward H2 — since gains in APMEA and AME will more than compensate for the moderation we'll see in the US during the second half.

Victoria Buxton

executive
#56

Duty drawback.

Tadeu Marroco

executive
#57

On duty drawback — yeah, during the first half it wasn't particularly significant. As for the second half, I won't be offering guidance on duty drawback, but it will be among the elements taken into account as we put our plans in place.

Pallav Mittal

analyst
#58

Thanks.

Tadeu Marroco

executive
#59

Alright.

Operator

operator
#60

Thanks. We’ll take the next question from Rey Wium at Anchor Stockbrokers. The line is yours — go ahead.

Rey Wium

analyst
#61

Yes, good day, Tadeu, Javed, and Victoria. If I may, to start off, I'd say Victoria is looking actually brilliantly in red. It serves as an opening there. Just I definitely get back to the guidance. Very strong performance on hitting on EPS, up 5.5%. Now, if I look at your guidance, you've talked about EPS middle of the range, so that basically 6.5%. You talk about translation impact negative 2 to 3%. That brings us back to sort of an adjusted EPS around about 4%. Am I more or less correct doing that assumption? That actually, overall, implies a bit of a slowdown in the EPS growth for the year. Within that, you've mentioned, obviously, the US will be slower, and the other two regions will be a bit stronger. I just want to know whether that summary is spot on.

Javed Iqbal

executive
#62

I think that when you consider how profit performed in H1 along with the full-year guidance we've given, it will indeed head in the right direction, meaning a more favorable effect on EPS. Yes, you're correct that after factoring in the FX impact, our adjusted EPS would land in the range of 4 to 4.5, which, just as a reminder, ranks among BAT's strongest EPS results in recent years, and our confidence is high. As I pointed out earlier, that is primarily driven by the kickers below operating profit, chiefly net finance cost, and also the cash conversion, and we do benefit from being a business that generates a high level of cash. Even in H1, we are delivering a high cash conversion, and we are on target to remain delivering above 95% conversion for the full year. Yes, you're right that our adjusted EPS would be more than 4%, around 4.5%.

Tadeu Marroco

executive
#63

On the basis we're using right now.

Javed Iqbal

executive
#64

If we’re talking about the current basis, then yes. Yeah.

Rey Wium

analyst
#65

Yeah, and just to add on that, for the new category growth you're guiding to mid-teens, and you had 18% in the first half. I just want to get a sense of whether you expect an improvement in heated products, which was down 12%? Then, obviously, I'm just curious about vapour growth, and whether we might see a bit of an acceleration there.

Tadeu Marroco

executive
#66

On vapour, clearly Vuse flavours are going to enter the market, but keep in mind what I said about that being phased, and most of the effect will be felt by you in 2027. We also need to factor in that we'll be lapping one competitor's exit in the US, which took place in the second half of last year, so those are the dynamics in vapour. For HP, I don't expect anything meaningful to change from a financial standpoint. I do expect that we'll recover share between now and the end of the year with all the actions we're putting in place. Velo, which is basically the reason we're growing in the mid-teens, will be lapping a much stronger comparator in the second half, because remember that in the first half of this year, we had essentially launched Velo Plus at the end of '24. They were still building up in the first half of '25. We'll just lap that half-year now in '26; they have very, very strong numbers in terms of volume and in terms of revenue, triple digits in the US. Obviously, when it comes to the second half of the year, they are lapping a much stronger second half of '25.

Tadeu Marroco

executive
#67

That is the sole reason we're pointing to the mid-teens for the full year.

Rey Wium

analyst
#68

That’s great — thanks a lot.

Operator

operator
#69

Thanks. For our last question, we have Richard Felton from Goldman Sachs on the line. Go right ahead.

Richard Felton

analyst
#70

Thanks. Morning, and I appreciate you fitting me in. I have two questions, please. The first is specifically about US vapour. When we consider how Vuse competes with the illicit segment, where do the gaps lie in terms of flavours, devices, and price points? Which of those gaps are you now able to close thanks to the FDA prioritization guidance? I suppose

Tadeu Marroco

executive
#71

So,

Richard Felton

analyst
#72

A pair of those.

Tadeu Marroco

executive
#73

If you’d like to ask one more question, let’s wrap this up—yes. You have one more question.

Richard Felton

analyst
#74

Or is that just Richard? That was the first one. The second one concerned free cash conversion. Obviously it was a little stronger than what we normally see from BAT in H1. The question is, what's driving that? Is it purely phasing between periods, or could that indicate potentially better cash conversion on a full-year basis as well? Thank you.

Tadeu Marroco

executive
#75

Alright. Javed, on the vape side, let's take free cash flow. On vapour, clearly the channel is where things get more interesting, right? Because as you likely noticed on my slide, we discussed illicit presence across channels — tracked channels sit at 12%, yet that represents only 2% of the legal market's size, since most illicit sales happen through independent vape stores. Flavours aren't the only issue; these players bring big-tank devices to market with an enormous puff count that we would never be permitted to offer. It isn't simply a matter of FDA approval, because we, as a responsible company, never commercialize any Vuse product anywhere in the world with a cartridge above 10 ml, which works out to roughly 4,000 puffs, since the more you puff, the metal degrades and contaminates the liquid you inhale — it's a bad vapour. Those illegal players don't care about that. You'll go out and buy a 10,000-puff and a 20,000-puff device. On my last market visit in the US, I saw one 100,000-puff device. Obviously, that delivers financial benefits when you look at the cost per puff of such a device.

Tadeu Marroco

executive
#76

Competing in that space is simply not possible for us. Enforcement has to shut this gap, since those products clearly should never have entered the market to begin with—they deliver no health benefit whatsoever, and if anything, the opposite. Where we will be leveling the field is in the convenience store channel, where since January 2021 we have been unable to offer flavours. We will return there; it is a very significant channel too. Even more importantly, it is one where we have strong confidence in our ability, working through retailers, to verify IDs prior to selling these products—something that does not necessarily occur when you start selling indiscriminately through independent stores and other kinds of outlets. In that channel, I believe this will close the gap substantially, and we will be competitive. As for what this means for the overall illicit market, we will have to wait and see. I don't want to offer a proper estimate on that at this point. Yeah.

Javed Iqbal

executive
#77

Regarding cash conversion, I have a couple of things to mention. First, as I noted before, net financing cost came down because we repaid debt using proceeds from ITC. But even more significant, I believe the finance team deserves real credit for the ongoing effort they make alongside our commercial colleagues to emphasize cash every bit as much as profit. That emphasis has produced stronger cash results, and it gives me strong confidence that across the full year we will once again achieve cash conversion above 95% for the full year.

Tadeu Marroco

executive
#78

I wouldn’t expect anything much stronger than what we saw last year, since our history shows very strong cash conversion. What we delivered in H1 simply makes us more confident that this can be another year of very strong performance on that front.

Richard Felton

analyst
#79

Thanks a lot.

Operator

operator
#80

Appreciate it. At this point, I’d like to turn the call back to Victoria so she can offer any extra or closing comments. The floor is yours, ma’am.

Victoria Buxton

executive
#81

Thank you. I really appreciate all of you calling in with your questions. Unfortunately, we've run out of time, so we won't be able to address the questions submitted online. However, anyone who sent something in will hear back from the IR team directly. At this point, I'll turn things over to Tadeu for his closing remarks.

Tadeu Marroco

executive
#82

Thanks to everyone for tuning in today and for every question you sent our way. So, by way of wrapping up, the first-half results came in as we had anticipated, and we remain on course to meet the guidance we set for the full year, with EPS now anticipated to land toward the midpoint of our 5 to 8% range. We'll keep rewarding shareholders via robust cash returns, which take in our progressive dividend along with a sustainable share buyback, and we'll keep delivering growth over the long term as well as value creation. Thanks once more for being with us. I hope to see plenty of you in September at our Capital Markets Day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete British American Tobacco p.l.c. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to British American Tobacco p.l.c. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in British American Tobacco p.l.c. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.